{"id":142958,"date":"2023-02-28T06:15:54","date_gmt":"2023-02-28T11:15:54","guid":{"rendered":"https:\/\/44.250.171.167\/?p=142958"},"modified":"2023-02-28T06:15:56","modified_gmt":"2023-02-28T11:15:56","slug":"earnings-dr-reddys-laboratories-ltd-nsedrreddy-q3fy23-results-out-total-income-rise-27-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-dr-reddys-laboratories-ltd-nsedrreddy-q3fy23-results-out-total-income-rise-27-yoy\/","title":{"rendered":"Earnings | Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY): Q3FY23 Results Out; Total Income rise 27% YoY"},"content":{"rendered":"\n

Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY)<\/a> is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy’s Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients (APIs), and proprietary products. The company’s product portfolio covers a wide range of therapeutic areas, including cardiovascular, oncology, gastroenterology, dermatology, and neurology, among others. In addition to its generic drug offerings, Dr. Reddy’s Laboratories also has a growing biosimilars business, which focuses on the development of high-quality and affordable biologic medicines. The company has a presence in over 25 countries, including the United States, Europe, Russia, India, and China.<\/p>\n\n\n\n

Dr. Reddy’s Laboratories, a pharmaceutical company based in India, has announced its Q3FY23 results. The company reported a gross profit margin of 59.2%, an increase of approximately 545 bps over the previous year. The increase was mainly driven by new product launches with higher margins, favorable product mix, and favorable forex movement, which was partly offset by price erosion. The gross profit margin for the GG and PSAI business segments were at 64.6% and 18.2%, respectively. The company’s SG&A expenses were Rs 18 billion, an increase of 17% YoY, primarily due to investments in sales and marketing, annual increments, certain one-off expenses, and higher forex rates. The R&D expenses were Rs 4.8 billion, and as a percentage of revenues, it was 7.1% in Q3FY23. <\/p>\n\n\n\n

The company continues its focus on investing in R&D to build a healthy pipeline of new products, including the development of products in its biosimilars and generics businesses. The company reported a profit before tax of Rs 16.3 billion, an increase of 68% YoY, and a profit after tax of Rs 12.5 billion. The diluted earnings per share were Rs 74.95, and the EBITDA was Rs 19.7 billion, with an EBITDA margin of 29.0%. The capital expenditure was Rs 2.9 billion, and the free cash flow was Rs 19.8 billion. Dr. Reddy’s Laboratories reported a net cash surplus of Rs 34 billion as of December 31, 2022, and the net debt-to-equity ratio was (0.15). The RoCE for the company was 35.8% (annualized).<\/p>\n\n\n\n

Overall, Dr. Reddy’s Laboratories had a positive Q3FY23, with an increase in gross profit margin, profit before tax, and RoCE, indicating a strong financial performance. The company continues to focus on investing in R&D and building a healthy pipeline of new products while maintaining a net cash surplus.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy’s Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients (APIs), and proprietary products. The […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[1115],"class_list":["post-142958","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":135275,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-limited-q2fy23-net-profit-increased-by-12\/","url_meta":{"origin":142958,"position":0},"title":"Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%","author":"Hardik Bhandare","date":"October 31, 2022","format":false,"excerpt":"Dr. Reddy's Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of \u20b963,318 Crore up from \u20b957,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to \u20b956,009 Crore. Consolidated Net Profit of \u20b911,142 up 12% from \u20b99,958 Crore in the same quarter\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171232,"url":"https:\/\/alphastreet.com\/india\/dr-reddy-q1-fy26-earnings-results\/","url_meta":{"origin":142958,"position":1},"title":"Dr Reddy Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 15, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Financial Highlights for Q1 FY26: Revenue: \u20b98,572 crore, up 11.38% year-on-year from \u20b97,696 crore Total Expenses:\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DRREDDY 1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139213,"url":"https:\/\/alphastreet.com\/india\/infographic-ltd-nse-drreddy-q3-fy23-results-total-income-rises-7-47-qoq\/","url_meta":{"origin":142958,"position":2},"title":"Infographic Ltd.(NSE: DRREDDY) | Q3 FY23 Results | Total Income rises +7.47% qoq","author":"Divyansh_Kasana","date":"January 25, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide range of generic and over-the-counter drugs, as well as active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 100 countries, with a focus on the developing\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143632,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-one-of-the-major-player-in-generic-segment\/","url_meta":{"origin":142958,"position":3},"title":"Dr. Reddy’s Laboratories: One Of The Major Player In Generic Segment","author":"Hardik Bhandare","date":"April 11, 2023","format":false,"excerpt":"\u201cWe are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The ANDA and DMF filings are expected to significantly improve during Q4. We are evaluating several inorganic opportunities across businesses in line with our strategy. We believe, all of\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":125277,"url":"https:\/\/alphastreet.com\/india\/key-highlights-from-dr-reddys-q2-2022-earnings-results\/","url_meta":{"origin":142958,"position":4},"title":"Key highlights from Dr Reddy\u2019s Q2 2022 earnings results","author":"Nishadkishore","date":"October 29, 2021","format":false,"excerpt":"Dr Reddy\u2019s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021. The company had total revenue of \u20b957.6 billion with a growth of 18% year on year. Dr Reddy's reported a net profit of \u20b99.92 billion or \u20b959.65 per share compared to \u20b97.62 billion\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":168307,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q4fy25-22-rise-in-profits\/","url_meta":{"origin":142958,"position":5},"title":"Dr. Reddy’s Laboratories Ltd Q4FY25; 22% rise in Profits","author":"Divyansh_Kasana","date":"May 9, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy's Laboratories reported Total revenue for Q4FY25 of \u20b9 9,050 Crore up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=142958"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142958\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=142958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=142958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=142958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}